This story was originally published on Feb. 9.
By Ben Butkus
Enigma Diagnostics has taken an important step toward commercializing its PCR-based, point-of-care molecular diagnostic platform by inking a global manufacturing and supply agreement with Tecan.
Enigma, based in Oxford, UK, said that it struck the alliance with Tecan in anticipation of a fourth-quarter commercial launch of its platform for point-of-care influenza diagnostic tests in Europe in partnership with GlaxoSmithKline.